関連する実験動画
Updated: Sep 9, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.0K
重度の喘息における生物学的治療の中止:安全な離脱のためのエビデンスと戦略:スケーピングレビュー
Johanna Ramirez-Villamizar1,2, Ciro D Ibarra-Enríquez3, Juan Sebastián Galindo-Sánchez1,3
1Universidad Icesi, Facultad de Ciencias de la Salud, Calle 18 No. 122-135, Cali, 760031, Colombia.
The World Allergy Organization journal
|September 2, 2025
まとめ
重度の喘息の生物学的治療を中止するには,慎重に検討する必要があります. 治療の終了後に寛解を維持し,悪化を避けるには,徐々に減量と個別化された計画が重要です.
科学分野:
- 肺科
- 免疫学
- 薬理学について
背景:
- 重度の喘息の治療には,しばしば高用量の吸入用コルチコステロイドと長時間作用する支氣管拡張剤が必要です.
- 生物学的治療は重度の喘息患者には寛解をもたらすが,最適な治療期間と安全な中止戦略は不明である.
研究 の 目的:
- 寛解中の重度の喘息患者の生物学的治療中止に関する証拠をレビューする.
- 生物学的中止後の悪化と炎症マーカーを含む臨床結果の評価.
主な方法:
- 2024年5月まで,PubMed,EMBASE,Epistemonikos,およびLILACSで包括的な文献レビューが行われました.
- 増悪,肺機能,およびバイオマーカーに焦点を当てた,生物学的投与量減少または停止後の喘息のコントロールを評価した研究が含まれていた.
主要な成果:
- テゼペルマブを中止すると,徐々にコントロールが失われ,メポリズマブを中止すると,1年以内に59%が悪化した.
- オマリズマブは異質な結果を示し,治療を継続した患者と比較して,治療中止後に悪化率が高かった.
- 漸進的な減量戦略は,臨床的コントロールを失うことなく治療中止の成功率を高くしました.
結論:
- 最低5年間の治療後に,生物学的治療の中止は個別化されるべきである.
- 治療中止の理想的な候補は,持続的なコントロール,安定した肺機能,および抑制されたバイオマーカーです.
- 徐々に投与量を減らす戦略は,離脱を最適化し,再発のリスクを最小限に抑えることができます.
関連する概念動画
01:17Drugs Used in Lower Respiratory Disorders: Overview
575
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
575
01:20Asthma: Pathogenesis and Management
576
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
576
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
451
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
451
01:30Asthma-IV: Diagnostic and Management
2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
383
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
383
01:26COPD: Management Using Bronchodilators and Corticosteroids
305
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
305